Acelrage is a drug made by Acel Therapeutics that was used to treat chronic fatigue syndrome.
The company is currently on hiatus.
A few weeks ago, Acel announced that it will delay the release of acelray to treat CFS.
Now, a few days after the news broke, Aeternity Pharmaceuticals is reporting that the company will delay its production of acranidazole, another drug for the disease.
The news comes a week after the company said it would not delay production of the drug it is currently developing.
“Due to limited availability, the Company intends to delay its clinical development of a cianidazone product for use in the treatment of chronic fatigue syndromes to be released by the end of September,” the company announced.
“Due to the high-level of safety and efficacy, we are committed to continuing development of the cianidex product.”
Aeternities said it is planning to release acronidazoles next month.
A cianazone has been shown to have a similar effect on the central nervous system.
It has also been shown in studies to be effective in treating severe anxiety, depression and fatigue, though the data on the effectiveness of this drug is still in its early stages.
Aetervan, a company that manufactures acromazone, said in a statement that it is not aware of any specific issues with the drug, but said that the drug’s timing of release “would be inconsistent with the Company’s ongoing focus on its ongoing development program.”
Acelrx Pharmaceuticals Inc., the company behind acros, said it will release a cranidaprovalone next month, but the company declined to say whether it would delay production for acroxyl.
The drug was initially developed as a treatment for patients with multiple sclerosis and was later marketed to treat multiple sclerosis patients.
Aetervans co-founder and CEO Jai Nair said in an interview with CNBC that Acelrx is “really committed to getting the drug to market and getting it to market as quickly as possible.”
“We’re really focused on getting this drug out in a timely manner, and that’s the way we think about this,” Nair added.
Acelrex has not said when the acramoxil will be ready for the market.
A Celos drug, a cyanocranidone, was approved in May and is available for the treatment and management of fatigue.